Author response to letter to the editor by Marciani et al.

Vaccine

Volumn 21, Issue 13-14, 2003, Pages 1303-

  Liu, Gui ^a   Kensil, Charlotte R ^b  

^a Antigenics Inc   (United States)

^b Antigenics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DICYCLOHEXYLCARBODIIMIDE; DODECYLAMINE; GPI 0100; IMINE; IMMUNOLOGICAL ADJUVANT; N HYDROXYSUCCINIMIDE; SAPONIN; SUCCINIMIDE DERIVATIVE; UNCLASSIFIED DRUG;

ACYLATION; AMIDATION; AQUEOUS SOLUTION; CHEMICAL REACTION; DEACYLATION; DRUG ACTIVITY; DRUG PURIFICATION; DRUG STABILITY; DRUG SYNTHESIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNIZATION; LETTER; MASS SPECTROMETRY; MOLECULAR WEIGHT; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; REACTION TIME;

ADJUVANTS, IMMUNOLOGIC; QUILLAJA; SAPONINS;

EID: 0037471405     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(02)00695-3     Document Type: Letter

References (4)

1. Marciani D.J., Pathak A.K., Reynolds R.C. Quillaja saponin adjuvants: derivatives formed under sub-optimal conditions. Vaccine. 20:2002;3237-3238.
2. Liu G., Anderson C., Scaltreto H., Barbon J., Kensil C.R. QS-21 structure/function studies: effects of acylation on adjuvant activity. Vaccine. 20:2002;2808-2815.
3. Marciani D.J., Press J.B., Reynolds R.C.et al. Development of semisynthetic triterpenoid saponin derivatives with immune stimulating activity. Vaccine. 18:2000;3141-3151.
4. Marciani DJ. Triterpene saponin analogs having adjuvant and immunostimulatory activity. US Patent 5,977,081, 1999.